June 27, 2022

Medical Trend

Medical News and Medical Resources

Takeda will merge the product lines of Pantoprazole and Vornola fumarate

Takeda will merge the product lines of Pantoprazole and Vornola fumarate



 

Takeda will merge the product lines of Pantoprazole and Vornola fumarate. 


On April 08,Takeda Pharmaceutical confirmed to the outside world that its two product lines in the digestive field: Pantoprazole sodium enteric-coated tablets and vornola fumarate raw tablets will be merged.

Vonola fumarate raw tablet is a new drug in the oral preparation market for peptic ulcer.

 

Takeda will merge the product lines of Pantoprazole and Vornola fumarate

 

 

Takeda Pharmaceutical  said that the main reason for this adjustment is to cope with the market environment and does not involve too many personnel adjustments.

 

Digestion is an area where Takeda Pharma has traditional strengths. It has a complete R&D pipeline, including core disease areas such as inflammatory bowel disease, celiac disease and other intestinal diseases, and gastrointestinal motility disorders.

Merging product lines is generally regarded as a routine action by pharmaceutical companies to reduce costs. This product line adjustment can be said to be an important layout of Takeda China in the field of digestion.

 

On the road to “paying off debts”

 

Takeda is the first and only Asian company to be ranked among the top 10 global pharmaceutical companies. This is thanks to its acquisition of Shire.

 

In January 2019, Takeda Pharmaceuticals acquired rare disease pharmaceutical giant Shire for $62 billion, the largest acquisition ever by a Japanese company.

While successfully ranking among the top ten biopharmaceutical companies in the world, Takeda also has a huge debt of more than 30 billion US dollars.

At the time, Takeda also announced a $10 billion non-core divestiture plan to sell 21 non-core assets, including its old headquarters.

 

So far, Takeda Pharmaceutical has embarked on the road of “payment of debts”.

 

According to incomplete statistics, in the two years from 2019 to 2020, Takeda Pharmaceutical sold about 10 assets, with a cumulative total of about 11.3 billion US dollars.

Including the sale of ophthalmic solutions and protein sealant patches to Novartis and Johnson & Johnson for $5.7 billion; the sale of rights to about 30 over-the-counter and prescription drugs in the Middle East and Africa to Swiss drugmaker Acino International for more than $200 million; and for $6.6 The sale of certain assets in Russia to Stada for $2.37 billion; the sale of consumer products business to Blackstone Group for $2.37 billion; the transfer of another 110 pharmaceutical products and two production sites to Orifarm in Denmark for $670 million company……

 

In addition to the divestment of projects in the above-mentioned areas.

 

In December 2020, Takeda Pharma sold non-core businesses such as product portfolios in the cardiovascular and metabolic fields in mainland China to Hessen Pharmaceuticals for a total transaction value of US$322 million, involving Yaningding, Yidabi, Bilos, Beix Xin and Aiketo 5 drugs. On March 31 this year, the transaction was officially completed, and Takeda China’s original staff responsible for these products were also transferred to Hessen.

 

This sell-off, which the outside world looks like a strong man’s broken wrist, has made Takeda’s debt reduction action come faster than expected.

 

Takeda Pharma has publicly stated that it plans to repay its debt through the proceeds of business divestiture between fiscal 2021 and fiscal 2023, and achieve its goal of doubling net debt/adjusted EBIT, and plans to achieve $47 billion in 2030. income.

 

In addition to debt factors, some industry insiders believe that the deeper reason for Takeda’s divestiture of non-core projects is the patent cliff problem commonly faced by multinational pharmaceutical companies.

 

From 2020 to 2030, there are more than ten types of medicines whose patents have expired, and 100% of them have an annual revenue of more than 30 billion yen, and more than 45% of them have an annual income of more than 50 billion yen.

 

According to industry insiders, business income is highly concentrated in a few products, which will bring great pressure to drug companies when the drugs enter the mature stage. Once the patent protection period expires, generic drugs will occupy a large area of ​​the market. If there is no relay of new products, pharmaceutical companies with highly concentrated products are very likely to experience a “cliff-like” decline in total revenue.

 

Therefore, in recent years, multinational companies have more and more frequently divested their mature products and focused on their core business.

 

In response to this issue, Takeda Pharmaceuticals responded that Takeda Pharmaceuticals has adjusted its company strategy since 2015, focusing on four therapeutic areas of oncology, rare diseases, neuroscience and digestion, and conducting research in the field of blood products (PDT) and vaccines. Special R&D investment.

 

Therefore, Takeda Pharma divested these mature products, while reducing debt, while retaining sufficient funds for the research and development of core products.

 

At this year’s JPM conference, Takeda CEO Christophe Weber said that once Vyvanse, Velcade and Azilva fell off the patent cliff, the support of 14 branded products including Takhzyro, Natpara and Entyvio, as well as the recently launched Exkivity and Livtencity, could sustain increase.

 

In addition, Takeda has been building its business in the more innovative areas of gene therapy and cell therapy.

 

On March 9, 2021, Takeda announced the acquisition of Maverick Therapeutics to enrich its T-cell solid tumor therapy and tumor immunotherapy pipelines.

 

In 2021, following the acquisition of Gamma Delta for its γδ T cell therapy platform, Takeda announced the acquisition of Adaptate Biotherapeutics for its antibody-based γδ T binder program.

 

As early as 2017, Takeda acquired Ariad Pharmaceuticals in the United States for US$5.2 billion, thereby obtaining Iclusig for the treatment of leukemia and Brigatinib for the treatment of non-small cell lung cancer, further improving its tumor pipeline.

 

Just last month, Takeda Brigatinib (Amberry) was approved by the State Drug Administration, and this approval marked Takeda China’s official entry into the field of lung cancer treatment. Amberry has been recommended by the “NCCN Clinical Practice Guidelines for Oncology” as the preferred drug for first-line clinical treatment.

 

After divesting and reducing investment in non-core projects, can Takeda usher in a new phase for development? Let’s look forward to it together.

 

 

 

 

 

 

 

 

 

 

 

 

References:

[1] Xiaowen goes southeast: “Behind Takeda’s 15.8 billion sale business is the anxiety and ambition of Asia’s No. 1 pharmaceutical company”

[2] Yaorongyun: “Takeda Pharmaceutical’s strong fiscal year 2020 results, 2021 guidance continues to climb”

[3] Health Knowledge Bureau: “Takeda divested its Chinese business for US$320 million, and the “best venture capital” Hefei Municipal Government took over the offer”

[4] Cyber ​​Blue: “Just now! Takeda China Exclusive Response: No Layoffs”

[5] Cyber ​​Blue: “Confirm! Adjustment of Blockbuster Product Lines of Well-known Pharmaceutical Companies”

Takeda will merge the product lines of Pantoprazole and Vornola fumarate

(source:internet, reference only)


Disclaimer of medicaltrend.org